Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
18:43:50 20/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 55.51 USD | -1.77% |
|
+4.03% | +25.31% |
| 08-10 | Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date | MT |
| 08-10 | Novo Nordisk works to address FDA's findings at Indiana plant | FW |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 6,882 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 53.16% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 6,565 | 6,477 | 6,512 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 53.76% | -1.34% | 0.54% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -17.4x | -22.1x | -36x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 25.9x | 23.2x | 25.7x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | 13.41x | 1x | 0.9x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 1,196x | 46.5x | 19.6x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 1,141x | 43.8x | 18.6x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -15.3x | -21.9x | -67.5x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -15x | -18.6x | -32.9x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -19.6x | -30.3x | -76.2x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -5.1% | -3.3% | -1.31% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.247 | -2.561 | -1.571 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 5.756 | 147.9 | 350.7 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -429 | -295.2 | -96.48 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -437.6 | -347.3 | -197.9 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -425.3 | -362.1 | -217.8 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -317.2 | -404.9 | -369.9 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 56.51 | 56.51 | 56.51 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 121,785 | - | - |
| Announcement Date | 07/03/22 | 07/03/23 | 19/03/24 | 27/02/25 | 03/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -17.4x | 1140.51x | -15.3x | -.--% | 6.88B | |
| 21.6x | 7.56x | 15.41x | 1.37% | 72.21B | |
| 36.46x | 9.42x | 28.89x | 0.04% | 63.98B | |
| -82.59x | 15.45x | -74.5x | -.--% | 28.53B | |
| 31.75x | 6.24x | 16.52x | -.--% | 25.07B | |
| -17.57x | 7.2x | -9.35x | -.--% | 28.42B | |
| 27.22x | 5.11x | 17.13x | -.--% | 20.04B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.19B | |
| 7705.33x | 40.58x | -1416.2x | -.--% | 15.96B | |
| 16.82x | 4.99x | 11.65x | -.--% | 13.48B | |
| Average | 777.45x | 125.66x | -138.61x | 0.17% | 29.28B | |
| Weighted average by Cap. | 431.80x | 37.48x | -70.02x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Select your edition
All financial news and data tailored to specific country editions
